107781-69-1

Basic information

• Product Name: novobiocin
• CAS NO: 107781-69-1
• Molecular Weight: 612.634
• Mol File: 107781-69-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: novobiocin(CAS DataBase Reference)
• NIST Chemistry Reference: novobiocin(107781-69-1)
• EPA Substance Registry System: novobiocin(107781-69-1)

Safety Data

• Hazardous Substances Data: 107781-69-1(Hazardous Substances Data)

Upstream product

• 1476-53-5 sodium novobiocin 
• 1445875-24-0 novobiocin 
• 590-55-6 carbamoyl phosphate 

Downstream Products

• 1445875-24-0 novobiocin 
• 1489273-46-2 C₂₈H₃₆N₂O₁₁ 
• 1489279-77-7 C₂₈H₃₀N₂O₁₁ 
• 1489281-74-4 C₂₉H₃₂N₂O₁₂ 
• 1449759-65-2 N-(7-{[3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-α-L-lyxohexopyranosyl]oxy}-4-methoxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl)-4-methoxy-3-(3-methyl-2-buten-1-yl)benzamide 
• 1343473-90-4 β-4'-O-(2,3,4,6-tetra-acetyl glucosyl) novobiocin 
• 95133-91-8 N-(4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)-4-hydroxy-3-isopentylbenzamide 
• 485-23-4 N-(4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide 
• 1343473-95-9 β-4'-O-galactosyl novobiocin 
• 1343473-91-5 β-4'-O-glucosyl novobiocin 
• 1343473-92-6 β-4'-O-(2,3,4,6-tetra-acetyl galactosyl) novobiocin 
• 1360870-34-3 C₂₇H₃₆N₂O₁₁ 
• 137553-19-6 3-prenyl-4-hydroxybenzoic acid isobutyrate 
• 1337988-14-3 C₃₇H₄₈N₄O₁₄S 

Relevant articles and documents

Characterization of NovP and NovN: Completion of Novobiocin Biosynthesis by Sequential Tailoring of the Noviosyl Ring

Two steps forward: The glycosylated aminocoumarin antibiotic novobiocin (1) is produced by. Streptomyces spheroides and inhibits the bacterial type II topoisomerase DNA gyrase. The sugar-tailoring enzymes NovP and NovN that catalyze the final two steps in novobiocin biosynthesis were overproduced in Escherichia coli and characterized as a methyltransferase and carbamoyltransferase, respectively.

Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors

Recent studies have shown that novobiocin (NB), a member of the coumermycin (CA) family of antibiotics with demonstrated DNA gyrase inhibitory activity, inhibits Heat shock protein 90 (HSP90) by binding weakly to a putative ATP-binding site within its C-terminus. To develop more potent HSP90 inhibitors that target this site and to define structure-activity relationships (SARs) for this class of compounds, we have synthesized twenty seven 3-amido-7- noviosylcoumarin analogues starting from NB and CA. These were evaluated for evidence of HSP90 inhibition using several biological assays including inhibition of cell proliferation and cell cycle arrest, induction of the heat shock response, inhibition of luciferase-refolding in vitro, and depletion of the HSP90 client protein c-erbB-2/HER-2/neu (HER2). This SAR study revealed that a substantial increase in biological activity can be achieved by introduction of an indole-2-carboxamide group in place of 4-hydroxy-isopentylbenzamido group at C-3 of NB in addition to removal/derivatization of the 4-hydroxyl group from the coumarin ring. Methylation of the 4-hydroxyl group in the coumarin moiety moderately increased biological activity as shown by compounds 11 and 13. Our most potent new analogue 19 demonstrated biological activities consistent with known HSP90-binding agents, but with greater potency than NB.

Steroid derived antibiotics

A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromycin and novobiocin.